Evidence map›Paper›PMID 32276137›Full record

ReviewClinical immunology (Orlando, Fla.)2020

Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic.

Amin Gasmi, Sadaf Noor, Torsak Tippairote, Maryam Dadar, Alain Menzel, Geir Bjørklund

Abstract readReview
In one paragraph

Review in Clinical immunology (Orlando, Fla.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. The epidemiological and radiographical characteristics of asymptomatic infections with the novel coronavirus (COVID-19): A systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Design, Synthesis and Biological Exploration of NovelInternational journal of molecular sciences · 2024
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Amin GasmiSociété Francophone de Nutrithérapie et de Nutrigénétique Appliquée, Villeurbanne, France.
Sadaf NoorInstitute of Molecular Biology and Biotechnology, Bahauddin Zakariya University Multan, Pakistan.
Torsak TippairoteNutritional and Environmental Medicine Department, BBH Hospital, Bangkok, Thailand; Faculty of Medicine, Ramathibodi Hospital and Institute of Nutrition, Mahidol University, Bangkok, Thailand.
Maryam DadarRazi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.
Alain MenzelLaboratoires Réunis, Junglinster, Luxembourg.
Geir BjørklundCouncil for Nutritional and Environmental Medicine (CONEM), Mo i Rana, Norway. Electronic address: bjorklund@conem.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is an ugly fact that a significant amount of the world's population will contract SARS-CoV-II infection with the current spreading. While a specific treatment is not yet coming soon, individual risk assessment and management strategies are crucial. The individual preventive and protective measures drive the personal risk of getting the disease. Among the virus-contracted hosts, their different metabolic status, as determined by their diet, nutrition, age, sex, medical conditions, lifestyle, and environmental factors, govern the personal fate toward different clinical severity of COVID-19, from asymptomatic, mild, moderate, to death. The careful individual assessment for the possible dietary, nutritional, medical, lifestyle, and environmental risks, together with the proper relevant risk management strategies, is the sensible way to deal with the pandemic of SARS-CoV-II.

Indexed as

PandemicsAge FactorsAntiviral AgentsBetacoronavirusCommunicable Disease ControlCoronavirus InfectionsCOVID-19COVID-19 SerotherapyDietFemaleGastrointestinal MicrobiomeHumansHygieneImmunization, PassiveLife StyleMaleAntiviral AgentsAntiviral medicationCOVID-19DietHerbsLifestyleNutritionSARS-CoV-IISmoking

Identifiers

PMID32276137
PMCPMC7139252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.